Biocept, Inc. Stock

BIOCQ

US09072V6002

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets 14:59:12 2026-08-07 EDT			5-day change	1st Jan Change
0.000100 ^USD	0.00%		0.00%	-

24-04-26	Motion for Asset Sale Approved for Biocept, Inc.	CI
24-04-02	Motion for Asset Sale Approved for Biocept, Inc.	CI

Analysts' recommendations: Biocept, Inc.

23-04-14	Maxim Group Downgrades Biocept to Hold From Buy	MT
22-06-15	Maxim Group Adjusts Biocept Price Target to $4 From $5, Maintains Buy Rating	MT
22-02-02	Maxim Group Adjusts Biocept Price Target to $7 From $12, Maintains Buy Rating	MT
21-10-08	Biocept : Brookline Capital Assumes Coverage on Biocept With Buy Rating, $14 Price Target	MT

More recommendations

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCEPT, INC.	0.00%	0.00%	0.00%	-99.99%	262
GUARDANT HEALTH, INC.	+2.84%	-3.31%	+174.58%	+354.77%	21.7B
BIOMÉRIEUX	-0.68%	-0.95%	-42.34%	-20.79%	9.9B
10X GENOMICS, INC.	+3.39%	-0.99%	+334.06%	+25.49%	7.56B
LANTHEUS HOLDINGS, INC.	-0.04%	-0.07%	+86.25%	+53.22%	6.59B
CARIS LIFE SCIENCES, INC.	-0.78%	-7.56%	-40.74%	-	6.11B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.41%	+4.96%	-12.57%	-6.88%	6B
ANDON HEALTH CO., LTD.	+3.29%	+4.62%	+87.09%	+116.06%	4.7B
DIASORIN S.P.A.	+0.11%	-2.33%	-11.35%	-16.50%	4.27B
AUTOBIO DIAGNOSTICS CO., LTD.	-2.38%	+0.06%	-21.04%	-33.49%	2.79B
Average	+0.62%	+0.87%	+55.39%	+41.32%	6.96B
Weighted average by Cap.	+1.25%	-0.02%	+92.50%	+131.90%

See all sector performances

Biocept, Inc. is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. The Company has developed a patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, it is a commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample. The Company operates a clinical laboratory and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Companyâ€™s diagnostic assays in a facility located in San Diego, California. The assays the Company offers are classified as laboratory developed tests (LDT) under the CLIA regulations. The Companyâ€™s assays, performed on cerebral spinal fluid, have the potential to provide more contemporaneous information on the characteristics of a patientâ€™s disease.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-08-17	US$0.000000	-	51
26-08-10	US$0.000000	-100.00%	3

Delayed Quote OTC Markets

More quotes

Stock Market
Stocks
BIOCQ Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	110K 95.22K 89.33K 81.36K 153K 10.55M 155K 1.05M 410K 5.28M 414K 405K 17.57M	P/E 2021	-18.9x	P/E 2022	-0.28x
Enterprise Value	-678K -585K -549K -500K -940K -64.8M -953K -6.43M -2.52M -32.46M -2.54M -2.49M -108M	EV / Sales 2021	0.73x	EV / Sales 2022	0.32x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

24-04-26	Motion for Asset Sale Approved for Biocept, Inc.	CI
24-04-02	Motion for Asset Sale Approved for Biocept, Inc.	CI
23-10-24	Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index	CI
23-10-19	Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index	CI
23-10-13	Biocept, Inc. Filed for Bankruptcy	CI
23-09-21	Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer	CI
23-09-08	Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform	MT
23-09-08	Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	MT
23-09-08	Top Premarket Gainers	MT
23-09-08	Plus Therapeutics, Inc. Enters into License Agreement with Biocept for Cerebrospinal Fluid Tumor Cell Enumeration Assay	CI
23-08-30	Biocept, Inc. - Special Call
23-08-23	Certain Warrants of Biocept, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	CI
23-08-23	Certain Stock Options of Biocept, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	CI

23-10-16	Biocept : Bankruptcy - Form 8-K	PU
23-09-22	Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide Assay to Evaluate Patients with Leptomeningeal Metastases	AQ
23-09-21	Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases	BU
23-09-11	Biocept Signs CNSide Licensing Agreement with plus Therapeutics	AQ
23-09-08	Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics	BU

1 month	0		0
Current year	0		0
1 year	0		0.1
3 years	0		1.85
5 years	0		133.2
10 years	0		30,510.06

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/16/23	Robert Walsh	Other	Controller/Auditor	806	0.0549%
11/17/22	Quyen Dao-Haddock	Free	Director	10,000	0.0591%
7/8/22	Ivor Royston	Free	Director	10,000	0.0591%

Biocept, Inc. Stock

Stocks

BIOCQ

US09072V6002

Medical Equipment, Supplies & Distribution

Valuation: Biocept, Inc.

Chart: Biocept, Inc.

Latest news : Biocept, Inc.

Analysts' recommendations: Biocept, Inc.

Press Releases: Biocept, Inc.

Course Extremes

Latest insider transactions

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

	2021	2022
Net sales	61.25M 52.88M 49.61M 45.18M 84.96M 5.86B 86.13M 582M 228M 2.93B 230M 225M 9.76B	25.86M 22.32M 20.94M 19.07M 35.87M 2.47B 36.36M 246M 96.2M 1.24B 97.08M 94.98M 4.12B
Net income	-2.82M -2.44M -2.29M -2.08M -3.92M -270M -3.97M -26.81M -10.51M -135M -10.6M -10.37M -450M	-32.09M -27.7M -25.99M -23.67M -44.51M -3.07B -45.12M -305M -119M -1.54B -120M -118M -5.11B
Net Debt	-16.19M -13.98M -13.11M -11.94M -22.46M -1.55B -22.77M -154M -60.24M -776M -60.79M -59.47M -2.58B	-788K -680K -638K -581K -1.09M -75.34M -1.11M -7.48M -2.93M -37.75M -2.96M -2.89M -126M